What the name refers to
A dual GLP-1 and glucagon receptor agonist developed for obesity and metabolic disease; its regulatory position differs by market.
Evidence and regulatory context
Medical use or authorisation exists historically or in limited jurisdictions. Current availability, indications and legal classification must be checked against the regulator for the reader’s location.
Reading product records
Keep evidence from an authorised or trial formulation separate from an online vial carrying the same name. Product records should identify the exact active ingredient and form, measured peptide amount, batch, storage history and whether the document covers identity, quantity or both.
Primary research links
Use current regulator and study records rather than treating a catalogue description as medical evidence.